Weight Gain

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

I
IQVIANC - Durham
1 program
New Infant FormulaN/A1 trial
Active Trials
NCT05508750Completed420Est. Jan 2024
BI
Baxter InternationalIL - Deerfield
1 program
Numeta G13N/A1 trial
Active Trials
NCT04168749Unknown200Est. May 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IQVIANew Infant Formula
Baxter InternationalNumeta G13

Clinical Trials (2)

Total enrollment: 620 patients across 2 trials

NCT05508750IQVIANew Infant Formula

Growth and Safety Clinical Trial on a New Infant Formula

Start: Sep 2022Est. completion: Jan 2024420 patients
N/ACompleted
NCT04168749Baxter InternationalNumeta G13

Efficacy and Safety of Industrially Prepared 3 Chamber Bag Parenteral Nutrition for Premature Infant

Start: Nov 2019Est. completion: May 2020200 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space